Immune-related adverse events
,由 BJ Schneider 著作 · 2021 · 被引用 739 次 — Patients with immune therapy–induced hemolytic anemia may present with weakness, paleness, jaundice, dark-colored urine, fever, and heart murmur. Immune-related ... ,由 Q Yin 著作 · 2023 · 被引用 23 次 — Cutaneous immune-related adverse events (irCAEs) are the most common and usually occur first. Maculopapular rash (MPR), pruritus, and lichenoid dermatitis are ... ,2024年1月3日 — Cutaneous immune-related adverse events associated with immune checkpoint inhibitors · Cytokine release syndrome (CRS) · Diabetic ketoacidosis ... ,由 M Conroy 著作 · 2022 · 被引用 146 次 — Immune-related adverse events and the balancing act of immunotherapy ... The benefit from immune checkpoint inhibitors is tempered by immunologic ... ,由 A Chennamadhavuni 著作 · 2022 · 被引用 120 次 — Immune-related adverse events (irAEs) are a range of complications associated with the use of immune-checkpoint inhibitors (ICIs). Two major classes of ICIs ... ,由 CC Barron 著作 · 2023 · 被引用 7 次 — Immune-related adverse events (irAEs) are toxicities resulting from use of immune checkpoint inhibitors (ICIs). These side effects persist in some patients ... ,由 F Martins 著作 · 2019 · 被引用 1487 次 — The main treatment-related adverse events associated with ipilimumab were skin, gastrointestinal and renal toxicities. Treatment with nivolumab ... ,由 JM Michot 著作 · 2016 · 被引用 2048 次 — Polyarthritis or arthralgia has been reported in around 5% of patients with immune checkpoint blockade [19], [31], [33], [51]. A few cases of erythematous lupus ... ,由 S Das 著作 · 2019 · 被引用 756 次 — Of 90 patients treated with ICIs, 42.2% experienced IRAEs. The most common IRAEs were dermatologic (15.6%), gastrointestinal (14%) and endocrine (11%). In a ...
| 相關軟體 Immunet 資訊 | |
|---|---|
 Immune-related adverse events 相關參考資料
Clinical Characteristics and Treatment of Immune-Related ...
https://www.ncbi.nlm.nih.gov Management of Immune-Related Adverse Events in ...
由 BJ Schneider 著作 · 2021 · 被引用 739 次 — Patients with immune therapy–induced hemolytic anemia may present with weakness, paleness, jaundice, dark-colored urine, fever, and heart murmur. Immune-re... https://ascopubs.org Immune-related adverse events of immune checkpoint ...
由 Q Yin 著作 · 2023 · 被引用 23 次 — Cutaneous immune-related adverse events (irCAEs) are the most common and usually occur first. Maculopapular rash (MPR), pruritus, and lichenoid dermatitis are ... https://www.frontiersin.org Toxicities associated with immune checkpoint inhibitors
2024年1月3日 — Cutaneous immune-related adverse events associated with immune checkpoint inhibitors · Cytokine release syndrome (CRS) · Diabetic ketoacidosis ... https://www.uptodate.com Immune-related adverse events and the balancing act of ...
由 M Conroy 著作 · 2022 · 被引用 146 次 — Immune-related adverse events and the balancing act of immunotherapy ... The benefit from immune checkpoint inhibitors is tempered by immunologic ... https://www.nature.com Risk Factors and Biomarkers for Immune-Related Adverse ...
由 A Chennamadhavuni 著作 · 2022 · 被引用 120 次 — Immune-related adverse events (irAEs) are a range of complications associated with the use of immune-checkpoint inhibitors (ICIs). Two major classes o... https://www.ncbi.nlm.nih.gov Chronic immune-related adverse events in patients with ...
由 CC Barron 著作 · 2023 · 被引用 7 次 — Immune-related adverse events (irAEs) are toxicities resulting from use of immune checkpoint inhibitors (ICIs). These side effects persist in some patients ... https://jitc.bmj.com Adverse effects of immune-checkpoint inhibitors
由 F Martins 著作 · 2019 · 被引用 1487 次 — The main treatment-related adverse events associated with ipilimumab were skin, gastrointestinal and renal toxicities. Treatment with nivolumab ... https://www.nature.com Immune-related adverse events with immune checkpoint ...
由 JM Michot 著作 · 2016 · 被引用 2048 次 — Polyarthritis or arthralgia has been reported in around 5% of patients with immune checkpoint blockade [19], [31], [33], [51]. A few cases of erythematous lu... https://www.sciencedirect.com Immune-related adverse events and anti-tumor efficacy ...
由 S Das 著作 · 2019 · 被引用 756 次 — Of 90 patients treated with ICIs, 42.2% experienced IRAEs. The most common IRAEs were dermatologic (15.6%), gastrointestinal (14%) and endocrine (11%). In a ... https://jitc.bmj.com |